Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11554600 | 0.71 | GABRA1 (0.41) | L3MBTL1ALDH1A1CYP3A4CYP2C19CA1 | |
| SCHEMBL16593970 | 0.71 | GABRA1 (0.41) | L3MBTL1ALDH1A1CYP3A4CYP2C19CA12 | |
| SCHEMBL755136 | 0.70 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1CYP3A4CYP2C19POLB | |
| SCHEMBL28936248 | 0.69 | CYP3A4 (0.45) | L3MBTL1ALDH1A1CYP3A4CYP2C19POLB | |
| SCHEMBL6576803 | 0.68 | GABRA1 (0.46) | L3MBTL1ALDH1A1CYP3A4CYP2C19POLB | |
| SCHEMBL4667743 | 0.68 | GABRA1 (0.46) | L3MBTL1ALDH1A1CYP3A4CYP2C19CA1 | |
| SCHEMBL29414888 | 0.68 | GABRA1 (0.46) | L3MBTL1ALDH1A1CYP3A4CYP2C19CA1 | |
| SCHEMBL2044282 | 0.68 | GABRA1 (0.46) | L3MBTL1ALDH1A1CYP3A4CYP2C19POLB | |
| SCHEMBL1415493 | 0.67 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1CYP3A4CYP2C19POLB | |
| SCHEMBL6542720 | 0.67 | GABRA1 (0.41) | L3MBTL1ALDH1A1CYP3A4CYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806746-B2 | Di- and tri-cationic glycosylated antitumor ether lipids, L-gucosylated gaels and rhamnose-linked gaels as cytotoxic agents against epithelial cancer cells and cancer stem cells | THE UNIV OF MANITOBA (CA) | 2020-10-20 | — | — | US | disclosed |
| US-20170189438-A1 | DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells | THE UNIV OF MANITOBA (CA) | 2017-07-06 | — | — | US | disclosed |
| WO-2015179983-A1 | DI- AND TRI-CATIONIC GLYCOSYLATED ANTITUMOR ETHER LIPIDS, L-GUCOSYLATED GAELS AND RHAMNOSE-LINKED GAELS AS CYTOTOXIC AGENTS AGAINST EPITHELIAL CANCER CELLS AND CANCER STEM CELLS | THE UNIVERSITY OF MANITOBA (CA) | 2015-12-03 | — | — | WO | disclosed |
| US-9169283-B2 | Post-synthetic modification of nucleic acids by inverse diels-alder reaction | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20130085271-A1 | POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2013-04-04 | — | — | US | disclosed |
| EP-2531514-A2 | POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION | Deutsches Krebsforschungszentrum (DE) | 2012-12-12 | — | — | EP | disclosed |
| EP-2360167-A1 | Post-synthetic modification of nucleic acids by inverse Diels-Alder reaction | Deutsches Krebsforschungszentrum (DE) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011095336-A2 | POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085271-A1 | POST-SYNTHETIC MODIFICATION OF NUCLEIC ACIDS BY INVERSE DIELS-ALDER REACTION | DERA, ADAR, POLRMT | L3MBTL1 658/4885ALDH1A1 389/4885CYP3A4 2672/4885 |
| US-20170189438-A1 | DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells | UGCG, PNLIP, B3GAT3 | L3MBTL1 186/4885ALDH1A1 3588/4885CYP3A4 3734/4885 |
| US-10806746-B2 | Di- and tri-cationic glycosylated antitumor ether lipids, L-gucosylated gaels and rhamnose-linked gaels as cytotoxic agents against epithelial cancer cells and cancer stem cells | PNLIP, UGCG, LIPC | L3MBTL1 175/4885ALDH1A1 3576/4885CYP3A4 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.